Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Novo Nordisk ( (NVO) ) has provided an announcement.
Novo Nordisk announced the results of its REDEFINE 2 phase 3 trial on March 10, 2025, which demonstrated that its once-weekly subcutaneous treatment, CagriSema, achieved superior weight loss in adults with obesity or overweight and type 2 diabetes compared to a placebo. The trial, part of the global REDEFINE programme, showed that 89.7% of patients on CagriSema achieved a weight loss of 5% or more after 68 weeks, compared to 30.3% with placebo. The treatment was well-tolerated with mostly mild to moderate gastrointestinal side effects. These results are expected to support regulatory filings in the first quarter of 2026, potentially impacting Novo Nordisk’s market position in obesity and diabetes treatment.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. The company focuses on defeating serious chronic diseases, particularly diabetes, through scientific breakthroughs and expanding access to medicines. Novo Nordisk employs approximately 76,300 people across 80 countries and markets its products in around 170 countries. Its shares are listed on Nasdaq Copenhagen and the New York Stock Exchange.
YTD Price Performance: -0.40%
Average Trading Volume: 9,008,658
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $385.3B
See more insights into NVO stock on TipRanks’ Stock Analysis page.